Last reviewed · How we verify
NCT06716619
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Phase 1 trial testing Tumor Associated Lymph node T cell in Tumor Associated Lymph Node T Cell in 32 participants. Currently enrolling.
19 December 2026
Quick facts
| Lead sponsor | Guangzhou FineImmune Biotechnology Co., LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 13 February 2025 |
| Primary completion | 19 December 2026 |
| Estimated completion | 19 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tumor Associated Lymph node T cell — full drug profile →
- Serplulimab Injection — full drug profile →
Conditions studied
- Tumor Associated Lymph Node T Cell — all drugs for Tumor Associated Lymph Node T Cell →
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
- Immunotherapy — all drugs for Immunotherapy →
- Serplulimab Injection — all drugs for Serplulimab Injection →
Sponsor
Guangzhou FineImmune Biotechnology Co., LTD. — full company profile →
Who can join
Adults 18 to 75, any sex, with Tumor Associated Lymph Node T Cell or Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06716619
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tumor Associated Lymph node T cell
Trials testing the same drug.
- NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting
Other recruiting trials for Tumor Associated Lymph Node T Cell
Currently open trials in the same condition.
- NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting
Other Guangzhou FineImmune Biotechnology Co., LTD. trials
Trials by the same sponsor.
- NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
- NCT06942143 — An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting
- NCT03891706 — Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06716619 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou FineImmune Biotechnology Co., LTD.
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06716619.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing